1. Home
  2. Companies
  3. IMR
  4. Material Events

Imricor Medical Systems (ASX:IMR) — Material Events

ASX:IMR · 24 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 2 articles Significant 20 articles Notable 2 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
20
Imricor Advances MRI-Guided Cardiac Tech with FDA Submission of Advantage-MRMedium
Imricor submits Advantage-MR system for FDA 510(k) clearance, advancing MRI-guided cardiac procedures
6 Feb 2026 ·Regulatory Submission ·85
Imricor Builds Regulatory and Clinical Momentum with US$7.8M Q1 OutflowMedium
Imricor advances FDA approvals, clinical trials, and commercial momentum with US$7.8M Q1 cash outflow
28 Apr 2026 ·Quarterly Activities Report and Appendix 4C ·85
Imricor Advances FDA Approval with Major Human Factors Study CompletionMedium
Imricor Completes Key Human Factors Study, Advances FDA Approval Pathway
18 Sept 2025 ·Regulatory Update ·85
Imricor Files SEC Form 10, Paving Way for U.S. Market ExpansionHigh
Imricor files SEC Form 10, advancing U.S. reporting status amid early commercial stage and FDA clearances
19 Mar 2026 ·Form 10 Registration Statement ·85
Imricor Medical Systems Reports 69.5% Revenue Drop Amid Strategic FDA PushHigh
Imricor Medical Systems reports 69.5% revenue drop, $25.3M net loss, FDA clearance achieved post-year-end
25 Feb 2026 ·Appendix 4E - Preliminary Final Report ·Unexpected ·85
Imricor Advances FDA Filings and Expands European Market Amid Q3 Cash OutflowsMedium
Imricor advances FDA submissions, launches NorthStar in Europe, reports Q3 cash outflows of US$4.8M
22 Oct 2025 ·Quarterly Activities Report and Appendix 4C ·85
Imricor Raises A$60 Million to Accelerate US Launch and Clinical TrialsMedium
Imricor raises A$60 million to fund U.S. expansion and clinical programs
4 May 2026 ·Capital Raising ·85
Imricor Secures FDA Pediatric Clearances for NorthStar and Vision-MR CatheterMedium
Imricor obtains FDA clearance for pediatric use of NorthStar system and Vision-MR Diagnostic Catheter
2 July 2026 ·Regulatory Clearance ·85
Imricor Advances MRI-Guided Cardiac Care with FDA Submission of Vision-MR CatheterMedium
Imricor submits Vision-MR Diagnostic Catheter for FDA 510(k) approval, advancing MRI-guided cardiac ablation platform
1 Sept 2025 ·Regulatory Submission Announcement ·85
Imricor Achieves World-First MRI-Guided Pulsed Field Ablation MilestoneMedium
Imricor completes world’s first MRI-guided Pulsed Field Ablation procedure
20 Oct 2025 ·ASX Announcement ·85
Imricor Accelerates iCMR Cardiac Ablation with Key Regulatory Wins and Clinical AdvancesMedium
Imricor advances regulatory approvals, expands clinical trials and customer pipeline, reports 1H 2025 results with strong cash position
26 Aug 2025 ·Financial Results ·85
Imricor Secures FDA Nod for Groundbreaking NorthStar MRI Cardiac SystemHigh
Imricor gains FDA clearance for NorthStar MRI-native 3D cardiac mapping system
29 Jan 2026 ·Regulatory Approval Announcement ·85
Charité Hospital Joins Imricor’s VISABL-VT Trial, Advancing MRI-Guided Cardiac CareMedium
Charité Hospital joins Imricor's VISABL-VT trial as second global site
19 Dec 2025 ·Clinical Trial Update ·80
Imricor Breaks New Ground with MRI-Guided Cardiac Ablation MilestonesMedium
Imricor achieves world-first MRI-guided cardiac ablation milestones and advances clinical trials with US$5.2M Q4 cash outflow
28 Jan 2026 ·Quarterly Activities Report and Appendix 4C ·80
Imricor Advances US Market Bid with Form 10 Amendment and FDA ClearancesMedium
Imricor files Form 10 amendment; advances MRI-guided cardiac ablation commercialization with FDA clearances and ongoing clinical trials; reports 2025 net loss of $25.3M on early-stage revenues.
27 Apr 2026 ·Form 10 Amendment ·80
Imricor Seeks FDA Pediatric Approval to Expand NorthStar Market in USMedium
Imricor submits NorthStar for FDA pediatric label expansion to boost U.S. commercialization
8 Apr 2026 ·Regulatory Submission ·80
Imricor Advances Real-Time MRI Cardiac Ablation with New Approvals and TrialsMedium
Imricor advances regulatory approvals and clinical trials, expands sales team, maintains strong cash position in Q2 CY25
28 July 2025 ·Quarterly Activities Report and Appendix 4C ·80
Oklahoma Heart Institute Boosts Imricor’s VISABL-AFL Trial MomentumMedium
Oklahoma Heart Institute joins Imricor's VISABL-AFL trial as fourth U.S. site, accelerating FDA approval process
3 Feb 2026 ·Clinical Trial Site Announcement ·75
Imricor’s Revenue Halves as Losses Surge Amid European Expansion and Clinical TrialsMedium
Imricor reports $13.14M half-year loss on lower revenue, boosts liquidity with $42.8M equity raise
26 Aug 2025 ·Half-Year Financial Report ·75
Imricor Advances FDA Approval with Third PMA Module SubmissionMedium
Imricor submits third FDA PMA module for MR cardiac ablation devices
11 June 2026 ·Regulatory Submission ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.